Shots:

• The approval is based on four P-III studies evaluating Evrenzo (20/50/100mg) in CKD anemic patients on dialysis in Japan- demonstrating increment in hemoglobin level and is well tolerated among the patients- marking the first approval of the collaboration
• Astellas and FibroGen collaborated to develop Evrenzo for treating anemia in Japan- Europe- the Commonwealth of Independent States- the Middle East- and South Africa while FibroGen collaborated with AstraZeneca for Evrenzo in the US- China & other markets
• Evrenzo (PO) is a HIF-PH inhibitor- approved for anemia associated with CKD in both dialysis-dependent and non-dialysis-dependent patients with anticipates approval in the US & EU

Click here to­ read full press release/ article | Ref: Astellas | Image: Astellas